The incidence and survival of breast cancer (BC) vary across countries. This study aimed to determine risk factors for BC and estimate the overall survival rate in BC patients of the Golestan Cohort Study (GCS).
Methods
This case-control study was performed among participants of the GCS. Cases (N = 99) consisted of women who were diagnosed with BC and controls (n = 400) were selected out of women participating in the same cohort and had not developed any cancer during the follow-up period. Controls were frequency matched to case on both place of residency and 5-year categories of age.
Results
Considering confounding variables, logistic regression analysis manifested a reverse association between parity and BC (OR [odds ratio] = 0.87, 95% CI: 0.80-0.95, P = 0.001). In addition, we found women who had family history of any cancer (OR = 1.63, 95% CI: 1.02-2.60, P = 0.04) and long term oral contraceptive (OCP) use (≥10 years) (OR = 3.17, 95% CI: 1.27-7.95, P = 0.01) were at higher risk of BC. Of the total patients, 23 (23.2%) were died due to BC after a mean follow-up of 102.4 ± 5.31 months. Using the Kaplan-Meier analysis, the 5-year survival in these patients was 74%.
Conclusion
In the Golestan Cohort population, long term OCP use and family history of cancer were risk factors for BC, while parity was a protective factor. The 5-year survival of BC patients in the GCS is still lower relative to Europe and the United States.
oral contraceptive long-term use breast cancer risk Iran, parity protective factor breast cancer case-control study, Golestan cohort study breast cancer risk factors Iran, OCP use ten years breast cancer odds ratio, family history cancer breast cancer risk factor, breast cancer survival rate developing countries Iran, oral contraceptive pill breast cancer case-control study, parity inverse association breast cancer risk, breast cancer incidence survival Golestan population-based, Alipour Malekzadeh breast cancer risk factors cohort
Cite this article
Alipour, S., omranipour, R., Malekzadeh, R., Poustchi, H., Pourshams, A., khoshnia, M., Gharavi, A., Roshandel, G., & Eslami, B. (2019). A Case-Control Study of Breast Cancer in Northeast of Iran: The Golestan Cohort Study. *Archives of Iranian medicine*, *22*(7), 355-360.
Alipour S, omranipour R, Malekzadeh R, Poustchi H, Pourshams A, khoshnia M, et al. A Case-Control Study of Breast Cancer in Northeast of Iran: The Golestan Cohort Study. Arch Iran Med. 2019;22(7):355-360.
Alipour, Sadaf, et al. "A Case-Control Study of Breast Cancer in Northeast of Iran: The Golestan Cohort Study." *Archives of Iranian medicine*, vol. 22, no. 7, 2019, pp. 355-360.
Maurya AP et al., 2023
Open Access
Indian Journal of Cancer
The incidence of breast cancer in India has seen a rapid increase in recent years. Hormonal and reproductive risk factors for breast cancer have been affected by socioeconomic development. Studies on ...
General OB/GYN > Breast Health > Breast Cancer Risk FactorsContraception/Comparison > Hormonal Methods > Long-Term Health OutcomesResearch Methodology > Systematic Reviews > Case-Control Studies
Ichida M et al., 2015
Open Access
Asian Pacific Journal of Cancer Prevention : APJCP
Background: Low-dose oral contraceptives (OC) were approved by the Japanese Ministry of Health, Labor and Welfare in 1999, yet despite their contraceptive and non-contraceptive health benefits, only 5...
Contraception/Comparison > Oral Contraceptives > Cancer RiskGeneral OB/GYN > Breast Health > Breast Cancer Risk FactorsResearch Methodology > Study Design > Case-Control Studies
Thorbjarnardottir T et al., 2014
Open Access
Acta Oncologica (Stockholm, Sweden)
Background: Findings on potential interactive effects of oral contraceptives (OCs) and hormone replacement therapy (HRT) on breast cancer risk have been inconsistent. We aimed to use population-based ...
Contraception/Comparison > Oral Contraceptives > Breast Cancer RiskPerimenopause/Menopause > Hormone Replacement Therapy > Breast CancerContraception/Comparison > Long-term Effects > Cancer Risk
Kotsopoulos J et al., 2014Breast Cancer Research and Treatment
It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contracepti...
Contraception/Comparison > Oral Contraceptives > Breast Cancer RiskContraception/Comparison > Genetic Risk Factors > BRCA1 Mutation CarriersGeneral OB/GYN > Cancer Risk > Hereditary Breast Cancer